video corpo

Roche in Brief - 32 Pages

Add to MyMedicalExpo favorites
Roche in Brief

Catalog excerpts

Key Figures 2012 Group sales Core operating profit Core earnings per share Operating free cash flow R & D investment Dividend 2 millions of CHF millions of CHF CHF millions of CHF millions of CHF CHF Total Shareholder Return 2012 The value of CHF 100 3 invested 1/1/2012, for the period ending 31/12/2012 125 121 Patients on clinical trials 4 Number of employees  patients employees 1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP=1.40. 4 Full-time equivalents.

 Open the catalog to page 3

Key Events 2012 Roche Group 3% Shareholders authorised a 3% dividend increase to CHF 6.80. It was the com­ any’s p 25  t h dividend increase in as many years. O’Day Management changes: Daniel O’Day was appointed the new Head of Roche Pharma, Roland Diggelmann, the new Head of Roche Diagnostics. Roche continued to streamline its research and develop­ment activities, taking the decision to close its site in ­ utley, New Jersey, N USA. Our late-stage pipeline made considerable progress in 2012, with 11 out of 14 clinical trials delivering positive results. The FDA approved Erivedge...

 Open the catalog to page 4

Corporate Sustainability In 2012 we reduced our water consumption by 8.6% and our greenhouse gas emissions by 2.6%. The second TransnetPhelophepa Healthcare Train was i ­naugurated in South Africa. Together the two trains reach over 550,000 people a year. Roche has been recognised as a great place to work, achieving top rankings in prestigious award listings worldwide in 2012. Roche has been named Healthcare Supersector Leader in the Dow Jones Sustainability Indexes (DJSI) for the fourth consecutive year. New US guidelines recognise the benefit of genotyping the human papillomavirus (HPV)...

 Open the catalog to page 5

At Roche, we focus on fitting treatments to patients through innovative medicines and diagnostic tests. A global leader in innovation Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. A sustainable company We are committed to sustainability and to running our business in a way that is ethical, responsible and creates long-term value. research centres patients in clinical trials A great workplace We are driven by a shared set of stan­ ards of integrity, d the courage to reach beyond boundaries and a passion for what we do....

 Open the catalog to page 6

What we do Pharmaceuticals We are the world’s largest biotech company with a product portfolio of truly differentiated therapies and a robust pipeline of investigational new medicines. Diagnostics We are the global leader in in vitro diagnostic testing for early detection, evaluation and monitoring of disease. We are also a frontrunner in the management of diabetes. 3 Sales by therapeutic area 2012 (CER)  3 Sales by business area 2012 (CER)  2% Central nervous system (+1%) 14% Other therapeutic areas (–4%) Pharmaceuticals sales Diagnostics sales Roche Group sales billion CHF billion CHF...

 Open the catalog to page 7

OUR STRATEGIC PRIORITIES Patients in need Personalised Healthcare Innovative pricing models Stakeholder value Roche in Brief 2012 | Roche at a Glance We strive to help patients in need with truly differentiated diagnostics and medicines. Our focus lies in five disease areas with unmet medical need, oncology, inflammation, infectious disease, metabolism and the c ­ entral nervous system. Personalised Healthcare at Roche is about providing the right therapy for the right group of patients at the right time. We provide medicines and diagnostics that optimise patient care, enabling tangible...

 Open the catalog to page 8

29 million cancer 70 million hepatitis C 24 million schizophrenia 235 illion asthma m 346 illion diabetes m PERSONALISED HEALTHCARE IN-HOUSE CUTTING EDGE SCIENCE OPTIMAL RESOURCE ALLOCATION EXTERNAL INNOVATION ESTABLISHED MARKETS Pressure from more active payers EMERGING MARKETS Build-up of healthcare systems with tight cost parameters

 Open the catalog to page 9

TOP-SELLING PHARMACEUTICALS in millions of CHF HER2-positive breast cancer, advanced HER2-positive stomach cancer colorectal ­c ancer, breast cancer, nonsmall cell lung cancer, kidney ­c ancer, ovarian cancer, ­glioblastoma colorectal ­c ancer, colon cancer, breast cancer MabThera/ Rituxan 1 Sales growth (CER)  non-Hodgkin’s lymphoma, chronic­ ­l ymphocytic ­leukemia, ­r heumatoid arthritis, ANCA-asso­ ciated vasculitis 1 CER: Constant exchange rates (average full-year 2011). Roche in Brief 2012 | Roche at a Glance

 Open the catalog to page 10

TOP-SELLING DIAGNOSTICS in millions of CHF Accu-Chek Nano SmartView cobas e modules, cobas c modules, Cobas Cobas Integra 1 Sales growth (CER)  Market segment Blood glucose Immunoassays monitoring Clinical chemistry Virology (hepatitis B and C, HIV) Advanced tissue staining Professional ­Diagnostics Tissue ­Diagnostics Business area Diabetes Care Professional ­Diagnostics Molecular ­Diagnostics

 Open the catalog to page 11

FINANCIAL PERFORMANCE Roche delivered a strong performance in 2012, reaching its financial targets for the year. Group sales increased 4% to 45.5 billion Swiss francs (+7% in Swiss francs). This reflected strong demand for oncology products, as well as for clinical lab diagnostic products. The US and emerging markets, especially China and Brazil, were the main regional growth drivers. In Western Europe, however, despite some resilience to pricing pressure, sales were slightly lower and there was additional pressure from generic competition. Outlook 2013 Roche expects Group sales in 2013 to...

 Open the catalog to page 12

Key figures Group sales Core operating profit Net income millions of CHF millions of CHF millions of CHF 1 Constant exchange rates (average full-year 2011). Financial overview In millions of CHF 2012 Group sales Core operating profit Operating free cash flow Core earnings per share (CHF) Pharmaceuticals Division — Diagnostics Division — 46% Europe, Middle East and Africa (EMEA) (–1%)

 Open the catalog to page 13

Excellence in science through discovery and innovation is our answer to the medical challenges the world faces. By continuously investing in research and development (R & D), we seek to gain a better understanding of disease and ­ arness the potential of modern biological sciences in h treating those diseases. That is why Roche has invested more than 75 billion Swiss francs in R & D over the past ten years — more than most other companies in the world.

 Open the catalog to page 14

Archived catalogs

  1. Roche in Brief

    32 Pages